The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. argenex SE (ARGX) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
argenex SE is a member of the Medical sector. This group includes 918 individual stocks and currently holds a Zacks Sector Rank of #9. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. argenex SE is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ARGX's full-year earnings has moved 7.8% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, ARGX has gained about 4.4% so far this year. In comparison, Medical companies have returned an average of 0.4%. This means that argenex SE is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Cardinal Health (CAH). The stock is up 14.7% year-to-date.
Over the past three months, Cardinal Health's consensus EPS estimate for the current year has increased 5.2%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, argenex SE belongs to the Medical - Biomedical and Genetics industry, a group that includes 440 individual stocks and currently sits at #108 in the Zacks Industry Rank. On average, this group has gained an average of 3.3% so far this year, meaning that ARGX is performing better in terms of year-to-date returns.
In contrast, Cardinal Health falls under the Medical - Dental Supplies industry. Currently, this industry has 14 stocks and is ranked #68. Since the beginning of the year, the industry has moved -1.3%.
Investors interested in the Medical sector may want to keep a close eye on argenex SE and Cardinal Health as they attempt to continue their solid performance.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
argenex SE (ARGX): Free Stock Analysis Report
Cardinal Health, Inc. (CAH): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).